205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2016
At a glance
- Drugs Sirukumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 07 Nov 2016 Status changed from recruiting to suspended.
- 11 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.